Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NTP 42

Next Previous
Search
Drug Profile

NTP 42

Alternative Names: NTP-42; NTP42:KVA4

Latest Information Update: 10 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ATXA Therapeutics
  • Developer ATXA Therapeutics; Hammersmith Medicines Research
  • Class Antihypertensives; Antineoplastics; Cardiovascular therapies; Heart failure therapies; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pulmonary arterial hypertension
  • Preclinical Cardiovascular disorders; Heart failure
  • Research Cancer; Genitourinary disorders

Most Recent Events

  • 10 Dec 2024 ATXA Therapeutics plans a phase II trial for Pulmonary arterial hypertension in Europe and North America (ATXA Therapeutics website, December 2024)
  • 09 Dec 2024 Phase I development is ongoing for Pulmonary arterial hypertension (PO, Suspension) in United Kingdom (ATXA Therapeutics pipeline, December 2024)
  • 09 Dec 2024 ATXA Therapeutics has patent protection for thromboxane receptor antagonists in the US, the European Union, Australia, Japan and Canada (ATXA Therapeutics website, December 2024)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top